ABSTRACT
Introducción: La leiomiomatosis esofágica es una neoplasia benigna con una incidencia dentro de los tumores del esófago extremadamente baja y en ocasiones difícil de categorizar como neoplasia o miopatía. Caso clínico: Se reporta el caso de una joven de 24 años que consultó por disfagia pro- gresiva de un año de evolución y antecedente de haberle descubierto una "mancha" en el pulmón diez años atrás. Las imágenes muestran masa que ocupa el tercio medio e inferior del esófago y megaesófago proximal por obstrucción a nivel de cardias. Se rea- lizó esofagectomía total, tubulización y ascenso gástrico con piloroplastía más anastomosis esófago gástrica latero lateral a nivel cervical. La patología confirmó la histología de leiomiomatosis esofágica. Conclusión: Es una patología muy rara con pocos casos reportados.
Introduction: Esophageal leiomyomatosis is a benign neoplasm with an extremely low incidence of esophageal tumors and is sometimes difficult to categorize as a neoplasm or myopathy. Clinical Case: The case of a 24-year-old girl, who consulted for progressive dysphagia of one year of evolution and a history of having discovered a "spot" on her lung ten years ago, is reported. The images show a mass that occupies the middle and lower third of the esophagus and proximal megaesophagus due to obstruction at the level of the cardia. Total esophagectomy, tubulization and gastric ascent with pyloroplasty plus lateral esophagogastric anastomosis at the cervical level were performed. The pathology confirms the histology of esophageal leiomyomatosis. Conclusion: It is a very rare pathology with few reported cases.
Subject(s)
Humans , Female , Adult , Esophageal Neoplasms/surgery , Leiomyomatosis/diagnosis , Leiomyoma , Biopsy , Diagnostic Imaging , Immunohistochemistry , Jejunostomy , Thoracotomy , Deglutition Disorders , Esophagectomy , Diagnosis, Differential , EndoscopyABSTRACT
Introducción. Los aspectos y desafíos éticos en la atención del paciente portador de patología esofágica incluyen diversas situaciones que deben ser anticipadas y conocidas por los expertos para poder solucionarlas de la manera más adecuada, favorable y justa para los enfermos y sus familiares. Métodos. Se realizó una revisión y análisis de la información disponible en las bases de datos con el fin de establecer los aspectos éticos relevantes para la cirugía esofágica en la actualidad. Discusión. Todos los cirujanos enfrentamos situaciones que conllevan a conflictos éticos en la práctica asistencial diaria. Un cirujano capaz e idóneo debe ser no sólo competente para llevar a cabo el arte y la ciencia de la cirugía, como se lo interpreta tradicionalmente, sino también para ser confiable desde el punto de vista ético y moral. Conclusión. Los principios éticos son de fundamental importancia y sirven de guía para el desempeño del cirujano ético, humanista y competente, y para afianzar la relación diádica entre enfermo y cirujano. El diálogo permanente, la resolución de eventuales conflictos, el reconocimiento de la vulnerabilidad del enfermo y la adhesión a los principios éticos deberán guiar el accionar de los profesionales a lo largo del proceso de atención quirúrgica, poniendo el bienestar y el interés del enfermo en primer lugar.
Introduction. The ethical aspects and challenges in the care of patients with esophageal pathology include different situations that must be anticipated and known by experts to be resolve in the most appropriate, favorable, and fair manner for the patients and their families. Methods. A review and analysis of the information available in the databases was carried out in order to establish the relevant ethical aspects of esophageal surgery today. Discussion. All surgeons face situations that lead to ethical conflicts in their daily care practice. A capable and suitable surgeon must be not only competent to carry out the art and science of surgery, as traditionally interpreted, but also ethically and morally trustworthy. Conclusion. Ethical principles are of fundamental importance and serve as a guide for the performance of the ethical, humanistic, and competent surgeon, and to strength the dyadic relationship between patient and surgeon. Permanent communication, resolution of possible conflicts, recognition of the patient's vulnerability, and adherence to ethical principles should guide the actions of professionals throughout the surgical care process, putting the well-being and interest of the patient first.
Subject(s)
Humans , Esophageal Diseases , Ethics, Medical , General Surgery , Esophageal Neoplasms , Ethics, ProfessionalABSTRACT
Introducción. La esofagectomía mínimamente invasiva (EMI) ha venido ganando popularidad debido a los resultados obtenidos en términos de seguridad, mortalidad, complicaciones y calidad de vida, así como los resultados oncológicos comparables a los obtenidos con la cirugía por vía abierta. Métodos. Estudio de cohorte de pacientes en quienes se llevó a cabo una EMI en la Sociedad de Cirugía de Bogotá Hospital de San José, en Bogotá, D.C., Colombia, entre enero de 2008 y diciembre de 2020. Resultados. Se incluyeron 99 pacientes, 52 hombres y 47 mujeres, con una edad media de 56 años; 58 tenían enfermedades benignas y 41 neoplasias del esófago. En 76 se llevó a cabo un abordaje de McKeown y en 23 una esofagectomía transhiatal por laparoscopia con anastomosis cervical. El tiempo quirúrgico promedio fue de 240 minutos y la media del sangrado de 140 ml. Seis pacientes fallecieron (6 %) y hubo 21 complicaciones en 14 pacientes (14 %), con 8 fugas de la anastomosis esofagogástrica (8 %) y 4 pacientes con neumonía (4 %). Conclusiones. Los resultados obtenidos confirman que la EMI es un procedimiento factible y seguro, cuyos beneficios la han convertido en el abordaje de elección para la resección y reconstrucción del esófago. No obstante, se trata de una cirugía compleja, con una curva de aprendizaje prolongada, que debe ser realizada en centros con altos volúmenes y por cirujanos expertos. La selección de los pacientes debe hacerse de manera individual teniendo en cuenta las comorbilidades, los recursos disponibles y la experticia del grupo quirúrgico.
Introduction. Minimally invasive esophagectomy (MIE) has been gaining popularity due to the results obtained in terms of safety, mortality, complications and quality of life, as well as oncologic results comparable to those obtained with open surgery. Methods. Cohort study of patients in whom MIE was performed at Hospital de San José, in Bogotá, D.C., Colombia, between January 2008 and December 2020. Results. Ninety-nine patients were included, 52 men and 47 women, with a mean age of 56 years; 58 had benign diseases and 41 had neoplasms of the esophagus. A McKeown approach was performed in 76 and a laparoscopic transhiatal esophagectomy with cervical anastomosis in 23. The average surgical time was 240 minutes and the average bleeding was 140 ml. Six patients died (6%) and there were 21 complications in 14 patients (14%), with eight esophagogastric anastomosis leaks (8%) and four patients with pneumonia (4%). Conclusions. The results obtained confirm that MIE is a feasible and safe procedure, whose benefits have made the approach of choice for resection and reconstruction of the esophagus. However, it is a complex surgery, with a long learning curve, which must be performed in centers with high volumes and by expert surgeons. Patient selection must be done individually taking into account comorbidities, available resources and expertise of the surgical group.
Subject(s)
Humans , Minimally Invasive Surgical Procedures , Esophageal Diseases , Thoracoscopy , Esophageal Neoplasms , Esophageal Achalasia , EsophagectomyABSTRACT
Introducción. El tratamiento del cáncer de esófago ha evolucionado notablemente en los últimos años. Los nuevos abordajes permiten preservar el esófago en tumores tempranos, mediante técnicas endoscópicas, y en aquellos localmente avanzados, es posible realizar resecciones mínimamente invasivas en combinación con tratamiento oncológico. La innovación quirúrgica es necesaria para aumentar la eficacia terapéutica, sin embargo, ésta requiere un aprendizaje cuya curva impacta en los resultados obtenidos. El objetivo de este trabajo fue mostrar cómo incide la curva de aprendizaje en la morbimortalidad asociada al procedimiento. Métodos. Se tomó una cohorte de 128 pacientes con esofagectomía mínimamente invasiva por cáncer de esófago, realizadas entre enero de 2014 y diciembre de 2023. Se agruparon en dos etapas de manera cronológica, creando dos grupos de 64 pacientes cada uno. Se evaluaron variables demográficas, tipo de anastomosis realizada, tasa de complicaciones, anatomía patológica, días de internación y seguimiento. Resultados. No hubo una diferencia significativa entre los dos grupos en factores demográficos, como edad y sexo, tipos histológicos o sitio de la anastomosis. La morbilidad (complicaciones tipo III y IV de Clavien-Dindo) fue del 43,7 % en la primera etapa y del 23 % en la segunda, con una diferencia significativa (p=0,02). Conclusiones. En nuestra cohorte mostramos una diferencia estadísticamente significativa en cuanto a la morbilidad entre la primera y la segunda etapa, sin embargo, no hubo diferencias en la mortalidad. Los hallazgos sugieren así que la curva de aprendizaje de un procedimiento tiene un impacto negativo transitorio sobre los resultados.
Introduction. The treatment of esophageal cancer has evolved significantly in recent years. New approaches allow preserving the esophagus in early tumors, using endoscopic techniques, and in locally advanced tumors, it is possible to perform minimally invasive resections in combination with an oncological treatment. Surgical innovation is necessary to increase therapeutic efficacy; however, it requires learning curve whose impacts the results obtained. The objective of this work was to show how the learning curve affects the morbidity and mortality associated with the procedure. Methods. A cohort of 128 patients with minimally invasive esophagectomy due to esophageal cancer was included, performed between January 2014 and December 2023. They were grouped into two stages chronologically, creating two groups of 64 patients each. Demographic variables, type of anastomosis performed, complication rate, pathology types, hospital stay and follow-up were analyzed. Results. There was no significant difference between both groups in demographic variables, such as age and sex, histological types, or anastomosis site. Morbidity (Dindo-Clavien types III and IV complications) was 43.7% on the first stage and 23% in the second one, with a significant difference (p=0.02). Conclusions. In our cohort, we showed a statistically significant difference in morbidity between the first and second stages; however, there were no differences in mortality. The findings thus suggest that the learning curve of a procedure has a temporary negative impact on the results.
Subject(s)
Humans , Minimally Invasive Surgical Procedures , Esophageal Diseases , Learning Curve , Esophageal Neoplasms , Morbidity , EsophagectomyABSTRACT
Introducción. La ingestión por cáusticos es un problema de salud pública a nivel mundial debido a la alta carga de morbilidad, mortalidad y costos. Por eso, es indispensable tener conocimientos claros sobre la situación en la población adulta, sin extrapolar datos de manejo de población pediátrica. Métodos. Se realizó una revisión crítica de la información disponible con el fin de establecer los datos importantes en el manejo de la esofagitis por cáusticos en población adulta, incluyendo un análisis del tipo de ingesta, volumen, intencionalidad y edad, para ayudar a identificar de manera temprana las complicaciones susceptibles de manejo quirúrgico. Resultados. La endoscopia tiene un rol importante en las primeras 24- 48 horas para establecer la severidad del daño según la clasificación de Zargar, que combinada con la clasificación imagenológica permite alcanzar un mejor pronóstico. No hay un beneficio demostrado con el uso de inhibidores de bombas de protones, mitomicina C, sonda nasogástrica o prótesis esofágica para prevenir las estenosis. Los esteroides tienen beneficio en Zargar ≥ 2B (pero con compromiso de vía aérea) y hay datos prometedores con el uso de sucralfato a altas dosis. En complicaciones derivadas de estenosis se prefiere la dilatación con Savary-Guillard de manera temprana. Luego de 10 años de la ingesta se debe hacer seguimiento endoscópico cada 2 -3 años para tamización de cáncer escamocelular de esófago. Conclusión. La esofagitis por cáusticos es una condición con alta carga de morbilidad, cuyo pronóstico depende de las intervenciones tempranas y un manejo y seguimiento multidisciplinario.
Introduction. Caustic ingestion is a public health problem worldwide, due to a high burden of morbidity, mortality and costs. Therefore, it is essential to have clear knowledge in the adult population, without extrapolating management data from the pediatric population. Methods. A critical review of the available information was carried out in order to establish important data in the management of caustic esophagitis in the adult population, including an analysis of the type of intake, volume, intention and age, to help identify early complications susceptible to surgical management. Results. Endoscopy has an important role in the first 24-48 hours to establish the severity of the damage according to the Zargar classification, which combined with the imaging classification allows a better prognosis to be achieved. There is no demonstrated benefit from the use of PPI, mitomycin C, nasogastric tube or esophageal prosthesis to prevent strictures. Steroids have a benefit in Zargar ≥ 2B (with airway compromise) and there are promising data with the use of sucralfate at high-doses. In complications derived from stenosis, early dilation with Savary-Guillard is preferred. After 10 years of ingestion, endoscopic follow-up should be performed every 2-3 years to screen for esophageal squamous cell cancer. Conclusion. Caustic esophagitis is a condition with a high morbidity burden, whose prognosis depends on early interventions and multidisciplinary management and follow-up.
Subject(s)
Humans , Caustics , Esophageal Stenosis , Esophagitis , Steroids , Esophageal Neoplasms , DilatationABSTRACT
Introduction. Surgery remains the mainstay of treatment for most esophagogastric junction (EGJ) tumors. After the surgical resection of EGJ tumors, the anatomy of the esophageal hiatus of the diaphragm is severely altered, increasing the risk of postoperative hiatal hernia (HH). While HH is more often reported after esophagectomy, HH is a rare complication after laparoscopic total gastrectomy and occurs in only approximately 0.5% of patients. Clinical case. A laparoscopic total gastrectomy with D2 lymphadenectomy was performed on a patient with an esophagogastric junction tumor. No intraoperative complications occurred and the patient had an uneventful postoperative course. Two months after the operation, the patient was admitted to the emergency room due to diffuse abdominal and chest pain, vomiting, and hematemesis. The chest and abdominal CT scan showed herniation of several bowel loops into the right hemithorax. Results. Due to hemodynamic instability, an emergent laparotomy was performed and the hiatal hernia was repaired with mesh. The patient recovered well from the operation and was discharged after 10 days. Conclusions. Clinical presentation is often non-specific and warrants a high level of suspicion. Elective surgical repair is recommended for large and/or symptomatic HH. Emergent repair might be needed for complicated HH with incarceration, strangulation, or bowel perforation. Overall, incarcerated HH after laparoscopic total gastrectomy is rare but should be considered in patients with abdominal pain or vomiting during the postoperative course. A prompt diagnosis and treatment are critical to obtain favorable outcomes.
Introducción. La cirugía sigue siendo el pilar del tratamiento para la mayoría de los tumores de la unión esofagogástrica (UEG). Después de la resección quirúrgica de los tumores de la UEG, la anatomía del hiato esofágico se altera severamente, aumentando el riesgo de hernia hiatal (HH) postoperatoria. Mientras que la HH se informa con mayor frecuencia después de la esofagectomía, la HH es una complicación rara después de una gastrectomía total laparoscópica y ocurre en solo aproximadamente 0,5 % de los pacientes. Caso clínico. Se realizó una gastrectomía total laparoscópica con linfadenectomía D2 en un paciente con un tumor en la UEG. No presentó complicaciones intraoperatorias y cursó su postoperatorio sin incidentes. Dos meses luego de la operación, fue admitido en la sala de emergencias debido a dolor abdominal y torácico difuso, vómitos y hematemesis. La tomografía computarizada de tórax y abdomen mostró herniación de asas intestinales en el hemitórax derecho. Resultados. Debido a la inestabilidad hemodinámica, se realizó una laparotomía de emergencia y se reparó la hernia hiatal con malla. El paciente fue dado de alta después de 10 días. Conclusiones. La presentación clínica suele ser inespecífica y justifica un alto nivel de sospecha. Se recomienda la reparación quirúrgica electiva para HH grandes y/o sintomáticas. La reparación de emergencia puede ser necesaria para HH complicadas con encarcelamiento, estrangulación o perforación intestinal. Generalmente, una HH encarcelada después de la gastrectomía total laparoscópica es infrecuente, pero debe considerarse en pacientes con dolor abdominal o vómitos durante el curso postoperatorio. Un diagnóstico y tratamiento oportunos son críticos para obtener resultados favorables.
Subject(s)
Humans , Postoperative Complications , Gastrectomy , Hernia, Hiatal , Esophageal Neoplasms , Minimally Invasive Surgical Procedures , Esophagogastric JunctionABSTRACT
SUMMARY: Barrett's esophagus is a condition where the distal third of the esophagus changes its epithelial lining from non- keratinized stratified squamous to simple columnar. This cross-sectional descriptive study was conducted to characterize the esophageal mucosa in the third trimester of pregnancy and determine possible variants in its development and was carried out in the Morphology Laboratory of the Health Faculty of the Industrial University of Santander, Colombia, with 45 human fetuses in the third trimester of gestation (weeks 25-40). A section of the distal esophagus and the first portion of the cardial region of the stomach were obtained, and the histological sections were subjected to a fixation process with 5 % formaldehyde solution. The sections were stained with hematoxylin and eosin and were evaluated for the presence of epithelial change or glands in the esophageal lamina propria. The change from non- keratinized stratified squamous epithelium to simple columnar epithelium was observed in the esophageal mucosa in five fetuses (11.1 %). In 15 cases (33.3 %), the presence of mucous glands underlying the epithelium was determined. In two fetuses, simple columnar epithelium was observed in the esophageal mucosa and underlying submucosal glands (4.4 %). The lack of replacement of the columnar epithelium by squamous epithelium in the distal third of the esophagus and the presence of mucous glands in the last third of gestation may suggest the presentation of Barret's esophagus in adulthood and thus, a predisposition to develop esophageal adenocarcinoma.
El esófago de Barrett es una afección en la que el tercio distal del esófago cambia su revestimiento epitelial de escamoso estratificado no queratinizado a columnar simple. Este estudio descriptivo de corte transversal tiene como objetivo caracterizar la mucosa esofágica en el tercer trimestre del embarazo y determinar posibles variantes en su desarrollo y se realizó en el laboratorio de Morfología de la Facultad de Salud de la Universidad Industrial de Santander-Colombia, con 45 fetos humanos en el tercer trimestre de gestación (semanas 25-40). Se obtuvo una sección del esófago distal y la primera porción de la región cardial del estómago y las secciones histológicas se sometieron a un proceso de fijación con solución de formaldehído al 5 %. Los cortes se tiñeron con hematoxilina y eosina y se evaluaron determinando la presencia de cambio epitelial y glándulas en la lámina propia del esófago. El cambio de epitelio escamoso estratificado no queratinizado a epitelio cilíndrico simple se observó en la mucosa esofágica en cinco fetos (11,1 %). En 15 casos (33,3 %) se determinó la presencia de glándulas mucosas subyacentes al epitelio. En dos fetos se observó epitelio cilíndrico simple en la mucosa esofágica y glándulas submucosas subyacentes (4,4 %). La falta de reemplazo del epitelio cilíndrico por epitelio escamoso en el tercio distal del esófago y la presencia de glándulas mucosas en el último tercio de la gestación pueden sugerir la presentación de esófago de Barrett en la edad adulta y una predisposición a desarrollar adenocarcinoma de esófago.
Subject(s)
Humans , Barrett Esophagus/etiology , Esophageal Mucosa/pathology , Barrett Esophagus/complications , Esophageal Neoplasms/etiology , Adenocarcinoma/etiology , Cross-Sectional Studies , Epithelium/pathology , Fetus , Metaplasia/pathologyABSTRACT
SUMMARY: Esophageal cancer is one of the most aggressive gastrointestinal cancers. Invasion and metastasis are the main causes of poor prognosis of esophageal cancer. SPRY2 has been reported to exert promoting effects in human cancers, which controls signal pathways including PI3K/AKT and MAPKs. However, the expression of SPRY2 in esophageal squamous cell carcinoma (ESCC) and its underlying mechanism remain unclear. In the present study, we aimed to investigate the detailed role of SPRY2 in the regulation of cell proliferation, invasion and ERK/AKT signaling pathway in ESCC. It was identified that the expression level of SPRY2 in ESCC was remarkably decreased compared with normal tissues, and it was related to clinicopathologic features and prognosis ESCC patients. The upregulation of SPRY2 expression notably inhibited the proliferation, migration and invasion of Eca-109 cells. In addition, the activity of ERK /AKT signaling was also suppressed by the SPRY2 upregulation in Eca-109 cells. Our study suggests that overexpression of SPRY2 suppress cancer cell proliferation and invasion of by through suppression of the ERK/AKT signaling pathways in ESCC. Therefore, SPRY2 may be a promising prognostic marker and therapeutic target for ESCC.
El cáncer de esófago es uno de los cánceres gastrointestinales más agresivos. La invasión y la metástasis son las principales causas de mal pronóstico del cáncer de esófago. Se ha informado que SPRY2 ejerce efectos promotores en los cánceres humanos, que controla las vías de señales, incluidas PI3K/AKT y MAPK. Sin embargo, la expresión de SPRY2 en el carcinoma de células escamosas de esófago (ESCC) y su mecanismo subyacente aún no están claros. En el presente estudio, nuestro objetivo fue investigar el papel detallado de SPRY2 en la regulación de la proliferación celular, la invasión y la vía de señalización ERK/AKT en ESCC. Se identificó que el nivel de expresión de SPRY2 en ESCC estaba notablemente disminuido en comparación con los tejidos normales, y estaba relacionado con las características clínico-patológicas y el pronóstico de los pacientes con ESCC. La regulación positiva de la expresión de SPRY2 inhibió notablemente la proliferación, migración e invasión de células Eca-109. Además, la actividad de la señalización de ERK/AKT también fue suprimida por la regulación positiva de SPRY2 en las células Eca-109. Nuestro estudio sugiere que la sobreexpresión de SPRY2 suprime la proliferación y la invasión de células cancerosas mediante la supresión de las vías de señalización ERK/AKT en ESCC. Por lo tanto, SPRY2 puede ser un marcador de pronóstico prometedor y un objetivo terapéutico para la ESCC.
Subject(s)
Humans , Esophageal Neoplasms/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Esophageal Squamous Cell Carcinoma/metabolism , Membrane Proteins/metabolism , Immunohistochemistry , Biomarkers, Tumor , Blotting, Western , Extracellular Signal-Regulated MAP Kinases , Cell Proliferation , Proto-Oncogene Proteins c-aktABSTRACT
Introdução: A neoplasia de esôfago é o sétimo câncer mais frequentemente diagnosticado e a sexta principal causa de morte relacionada ao câncer no mundo. No Brasil, ocupa a 13ª posição entre os tipos de câncer mais frequentes. Os sítios mais comuns de disseminação do câncer esofágico são pulmão, fígado e ossos. As metástases do câncer de esôfago para a mama são extremamente raras e pouco documentadas na literatura. Relato do caso: Homem, 45 anos, diagnosticado com adenocarcinoma de esôfago após manifestar dispepsia e epigastralgia. A investigação por endoscopia digestiva alta revelou adenocarcinoma de esôfago, sem metástases a distância. Foi submetido à esofagectomia e quimioterapia adjuvante. Na tomografia por emissão de pósitrons (PET-CT), realizada pós-tratamento, foi detectada recidiva local, iniciando terapia paliativa. Pouco antes, uma nodulação na mama direita foi diagnosticada inicialmente como lesão primária da mama, carcinoma do tipo não especial, triplo-negativo. Contudo, uma revisão da lâmina revelou um adenocarcinoma pouco diferenciado metastático do esôfago, resultando em dois diagnósticos discordantes. Uma terceira análise do material da mama por imuno-histoquímica confirmou a lesão metastática secundária ao esôfago. Durante o tratamento, o paciente apresentou crise convulsiva, com diagnóstico de implante cerebral secundário. Realizou radioterapia em lesão do sistema nervoso central e mastectomia. O PET-CT revelou ausência de sinais de atividade metabólica anormal. Atualmente, encontra-se assintomático com programação terapêutica de imunoterapia de manutenção associada a bloqueio do HER2. Conclusão: Este caso sublinha a raridade da metástase mamária no câncer de esôfago e a importância crucial da imuno-histoquímica para um diagnóstico diferencial preciso e planejamento terapêutico adequado.
Introduction: Esophageal cancer is the seventh most frequently diagnosed cancer and the sixth leading cause of cancer-related death worldwide. In Brazil, it ranks 13th among the most common types of cancer. The most usual sites of metastatic esophageal cancer are lungs, liver, and bones. Metastases from esophageal cancer to the breast are extremely rare and poorly documented in the literature. Case report: A 45-year-old man was diagnosed with esophageal adenocarcinoma after presenting with dyspepsia and epigastralgia. Investigation via upper gastrointestinal endoscopy revealed esophageal adenocarcinoma with no distant metastases. He underwent esophagectomy and adjuvant chemotherapy. Post-treatment positron emission tomography (PET-CT) detected local recurrence, leading to the initiation of palliative therapy. Shortly before, a nodule in the right breast was initially diagnosed as a primary breast lesion, triple-negative carcinoma of no special type. However, a review of the slide revealed poorly differentiated metastatic adenocarcinoma from the esophagus, resulting in two discordant diagnoses. A third analysis of the breast material by immunohistochemistry confirmed a secondary metastatic lesion from the esophagus. During treatment, the patient had a seizure, with diagnosis of secondary brain implant. He underwent radiotherapy for the central nervous system lesion and mastectomy. PET-CT revealed no signs of abnormal metabolic activity. He is currently asymptomatic with therapeutic maintenance immunotherapy associated with HER2 blockade. Conclusion: This case highlights the rarity of breast metastasis in esophageal cancer and the crucial importance of immunohistochemistry for an accurate differential diagnosis and adequate therapeutic planning.
Introducción: La neoplasia de esófago es el séptimo cáncer más frecuentemente diagnosticado y la sexta principal causa de muerte relacionada con el cáncer en el mundo. En el Brasil, ocupa el 13º lugar entre los tipos de cáncer más frecuentes. Los sitios más comunes de diseminación del cáncer esofágico son los pulmones, el hígado y los huesos. Las metástasis del cáncer de esófago hacia la mama son extremadamente raras y poco documentadas en la literatura. Informe del caso: Hombre, 45 años, diagnosticado con adenocarcinoma de esófago después de manifestar dispepsia y epigastralgia. La investigación a través de una endoscopia digestiva alta reveló adenocarcinoma de esófago, sin metástasis a distancia. Se sometió a esofagectomía y quimioterapia adyuvante. En la tomografía por emisión de positrones (PET-CT), realizada después del tratamiento, se detectó recidiva local, iniciando terapia paliativa. Poco antes, una nodulación en la mama derecha fue diagnosticada inicialmente como lesión primaria de la mama, carcinoma del tipo no especial, triple negativo. Sin embargo, una revisión de la lámina reveló adenocarcinoma pobremente diferenciado metastásico del esófago, resultando en dos diagnósticos discordantes. Un tercer análisis del material mamario mediante inmunohistoquímica confirmó lesión metastásica secundaria al esófago. Durante el tratamiento, el paciente desarrolló una convulsión, con diagnóstico de implantación cerebral secundaria. Realizó radioterapia para lesiones del sistema nervioso central y mastectomía. La PET-CT no reveló signos de actividad metabólica anormal. Actualmente se encuentra asintomático con esquema terapéutico de inmunoterapia de mantenimiento asociada a bloqueo de HER2. Conclusión:Este caso resalta la rareza de las metástasis mamarias en el cáncer de esófago y la importancia crucial de la inmunohistoquímica para un diagnóstico diferencial preciso y una planificación terapéutica adecuada.
Subject(s)
Humans , Male , Breast Neoplasms , Esophageal Neoplasms , Immunohistochemistry , Adenocarcinoma , Neoplasm MetastasisABSTRACT
SUMMARY: This study is to investigate the effect of survivin down-regulation by Egr1-survivin shRNA combined with radiotherapy on the apoptosis and radiosensitivity of esophageal squamous cell carcinoma ECA109 and KYSE150 cells. ECA109 and KYSE150 cells were transfected with Egr1-survivin shRNA, and then treated with radiotherapy. After 24 h, the mRNA and protein levels of Egr1-survivin were detected by qPCR and Western-Blot. Cell cycle and apoptosis were detected by flow cytometry. Western blot also detected levels of cleavaged Caspase 3 and Caspase 9. YM155 was used as a positive control to inhibit survivin expression. The levels of survivin mRNA and protein in ECA109 and KYSE150 cells treated with Egr1-survivin shRNA combined with radiotherapy were significantly lower than those of the blank control group, the empty vector control group, and, the YM155 + radiotherapy group (P<0.05). Meanwhile, after survivin down-regulation, the ratio of G2 to S phase of ECA109 and KYSE150 cells increased significantly, leading to significant G2 and S phase arrest. Additionally, apoptosis of ECA109 and KYSE150 cells increased significantly (P <0.01). Further, protein levels of cleavaged Caspase 3 and Caspase 9 significantly increased in Egr1-survivin shRNA combined with radiotherapy group. Egr1-survivin shRNA combined with radiotherapy can down-regulate survivin expression, which further increases the apoptosis, and enhances the radiosensitivity of ECA109 and KYSE150 cells.
Este estudio tuvo como objetivo investigar el efecto de la regulación negativa de survivina por el shRNA de Egr1-survivina combinado con radioterapia sobre la apoptosis y la radiosensibilidad del carcinoma de células escamosas de esófago Células ECA109 y KYSE150. Las células ECA109 y KYSE150 se transfectaron con shRNA de survivina Egr1 y luego se trataron con radioterapia. Después de 24 h, los niveles de ARNm y proteína de Egr1-survivina se detectaron mediante qPCR y Western-Blot. El ciclo celular y la apoptosis se detectaron mediante citometría de flujo. La transferencia Western también detectó niveles de Caspasa 3 y Caspasa 9 escindidas. Se usó YM155 como control positivo para inhibir la expresión de survivina. Los niveles de ARNm y proteína de survivina en células ECA109 y KYSE150 tratadas con shRNA de survivina Egr1 combinado con radioterapia fueron significativamente más bajos que los del grupo control en blanco, el grupo control de vector vacío y el grupo de radioterapia YM155 + (P <0,05). Mientras tanto, después de la regulación negativa de survivina, la proporción entre las fases G2 y S de las células ECA109 y KYSE150 aumentó significativamente, lo que llevó a una detención significativa de las fases G2 y S. Además, la apoptosis de las células ECA109 y KYSE150 aumentó significativamente (P <0,01). Además, los niveles de proteína de Caspasa 3 y Caspasa 9 escindidas aumentaron significativamente en el shRNA de Egr1- survivina combinado con el grupo de radioterapia. El shRNA de survivina de Egr1 combinado con radioterapia puede regular negativamente la expresión de survivina, lo que aumenta aún más la apoptosis y mejora la radiosensibilidad de las células ECA109 y KYSE150.
Subject(s)
Humans , Esophageal Neoplasms/therapy , Survivin , Esophageal Squamous Cell Carcinoma/therapy , Radiation-Sensitizing Agents , Radiation Tolerance , RNA, Messenger , Esophageal Neoplasms/genetics , Esophageal Neoplasms/radiotherapy , Transfection , Down-Regulation , Blotting, Western , Apoptosis , Combined Modality Therapy , RNA, Small Interfering , Cell Line, Tumor/radiation effects , Early Growth Response Protein 1 , Caspase 3 , Caspase 9 , Real-Time Polymerase Chain Reaction , Flow Cytometry , Esophageal Squamous Cell Carcinoma/genetics , Esophageal Squamous Cell Carcinoma/radiotherapyABSTRACT
El esófago de Barrett (EB) se define como la condición en la cual una mucosa columnar metaplásica predispuesta a neoplasia reemplaza la mucosa escamosa del esófago distal. La guías actuales recomiendan que el diagnóstico requiere el hallazgo de metaplasia intestinal (MI) con células caliciformes de al menos 1 cm de longitud. El EB afecta aproximadamente al 1% de la población general y hasta en 14% de los pacientes con enfermedad por reflujo gastroesofágico (ERGE). El EB es precursor del adenocarcinoma esofágico (ACE), neoplasia en aumento en países occidentales. Los principales factores de riesgo descritos para ACE asociado a EB son: sexo masculino, edad > 50 años, obesidad central y tabaquismo. El riesgo anual de ACE en EB sin displasia, displasia de bajo (DBG) y alto grado es 0,1-0,3%, 0,5% y 5-8%, respectivamente. El tratamiento del EB no displásico consiste en un cambio de estilo de vida saludable, quimioprevención mediante inhibidores de la bomba de protones y vigilancia endoscópica cada 3 a 5 años. Se recomienda que a partir de la presencia de DBG los pacientes sean referidos a un centro experto para la confirmación del diagnóstico, estadio y así definir su manejo. En pacientes con EB y displasia o cáncer incipiente, el tratamiento endoscópico consiste en la resección y ablación, con un éxito cercano al 90%. El principal evento adverso es la estenosis esofágica que es manejada endoscópicamente.
Barrett's esophagus (BE) is the condition in which a metaplastic columnar mucosa predisposed to neoplasia replaces the squamous mucosa of the distal esophagus. The current guidelines recommends that diagnosis requires the finding of intestinal metaplasia (IM) with goblet cells of at least 1 cm in length. BE affects approximately 1% of the general population and up to 14% of patients with gastroesophageal reflux disease (GERD). BE is a precursor of esophageal adenocarcinoma (EAC), which has increased in western countries. The main risk factors described for EAC associated with BE are male sex, age > 50 years, central obesity and tobacco use. Annual risk of EAC in patients with BE without dysplasia, low grade (LGD) and high-grade dysplasia is 0,1-0,3%, 0,5% y 5-8%, respectively. Treatment of non-dysplastic BE consists mainly of a healthy lifestyle change, chemoprevention with proton pump inhibitors and surveillance endoscopy every 3 to 5 years. It is recommended that from the presence of LGD patients are referred to an expert center for confirmation of the diagnosis, stage and thus define their management. In patients with BE and dysplasia or early-stage cancer, endoscopic therapy with resection and ablation is successful in about 90% of the patients. The main adverse event is esophageal stricture, which is managed endoscopically.
Subject(s)
Humans , Male , Barrett Esophagus/diagnosis , Barrett Esophagus/etiology , Barrett Esophagus/therapy , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/etiology , Esophageal Neoplasms/therapy , Adenocarcinoma/diagnosis , Adenocarcinoma/etiology , Adenocarcinoma/pathology , Precancerous Conditions/diagnosis , Precancerous Conditions/therapy , Risk Factors , EsophagoscopyABSTRACT
Introdução: o câncer é um grave problema de saúde pública, considerado a segunda causa de óbitos no Brasil. Devido à sua relevância, é indispensável um controle eficiente dos casos através do acompanhamento da taxa de mortalidade. Dessa forma, o trabalho analisou a evolução da mortalidade por câncer para as localizações primárias mais frequentes, segundo sexo, durante o período de 2010 a 2020. Metodologia: trata-se de um estudo observacional descritivo, no qual os dados foram obtidos através do Atlas On-line de Mortalidade por Câncer. Os dados colhidos correspondem ao número de óbitos estratificados por tipo de câncer mais frequente, por ano estudado e por sexo, além das taxas de mortalidade específica bruta e a taxa de mortalidade ajustada por idade para o sexo masculino e feminino, para cada tipo de câncer em estudo, considerando a população padrão mundial, sendo avaliado por regressão linear a significância da tendência temporal. Resultados: no Brasil, no período de 2010 a 2020, as neoplasias mais frequentes em mulheres foram câncer de mama, câncer nos brônquios e pulmões, câncer no colo do útero, câncer no cólon e no pâncreas e em homens foram brônquios e pulmões, câncer de próstata, câncer de estômago, de esôfago e no fígado e vias biliares, sendo observado uma tendência crescente na taxa de mortalidade em mulheres e decrescente na taxa de mortalidade em homens. Conclusão: os resultados demonstram um possível comprometimento com a notificação durante o período de pandemia por Covid-19 e um possível rastreamento ainda deficiente de câncer na população masculina.
Introduction: cancer is a severe public health problem, considered the second cause of death in Brazil. Due to its relevance, efficient control of cases by monitoring the mortality rate is essential. Thus, the work analysed the evolution of cancer mortality for the most frequent primary locations, according to sex, from 2010 to 2020. Methodology: this is a descriptive observational study in which data were obtained through the Atlas Online Cancer Mortality Report. The data collected correspond to the number of deaths stratified by the most frequent type of cancer, by year studied and by sex, in addition to the crude specific mortality rates and the age-adjusted mortality rate for males and females, for each type of cancer. Understudy, considering the standard world population, the significance of the temporal trend is evaluated by linear regression. Results: in Brazil, from 2010 to 2020, the most frequent neoplasms in women were breast cancer, bronchial and lung cancer, cervical cancer, colon and pancreas cancer and in men, they were bronchial and lung cancer, cancer prostate, stomach, oesophagal and liver and biliary tract cancer, with an increasing trend in the mortality rate in women and a decreasing trend in the mortality rate in men. Conclusion: the results demonstrate a possible compromise with notification during the Covid-19 pandemic and a possible still poor screening of cancer in the male population.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Death , Neoplasms , Pancreatic Neoplasms , Prostatic Neoplasms , Stomach Neoplasms , Breast Neoplasms , Esophageal Neoplasms , Uterine Cervical Neoplasms , Epidemiology, Descriptive , Liver Neoplasms , Lung NeoplasmsABSTRACT
Introducción. El diagnóstico adecuado de los tumores de la unión esofagogástrica es esencial para el tratamiento de estos pacientes. La clasificación propuesta por Siewert-Stein define las características propias, factores de riesgo y estrategias quirúrgicas según la localización. El objetivo de este estudio fue describir las características de los pacientes con adenocarcinoma de la unión esofagogástrica tratados en nuestra institución. Métodos. Estudio retrospectivo, descriptivo, de corte longitudinal, que incluyó los pacientes con diagnóstico de adenocarcinoma de la unión esofagogástrica intervenidos quirúrgicamente en el Instituto Nacional de Cancerología, Bogotá, D.C., Colombia, entre enero de 2012 y mayo de 2017. Resultados. Se operaron 59 pacientes (84,7 % hombres), con una edad media de 62,5 años. En su orden de frecuencia los tumores fueron tipo II (57,6 %), tipo III (30,7 %) y tipo I (11,9 %). El 74,6 % recibieron neoadyuvancia y se realizó gastrectomía total en el 73 % de los pacientes. La concordancia diagnóstica moderada con índice Kappa fue de 0,56, difiriendo con la endoscópica en 33,9 %. El 10,2 % de los pacientes presentó algún tipo de complicación intraoperatoria. La supervivencia a tres años en los tumores tipo II fue del 89,6 % y del 100 % en aquellos con respuesta patológica completa. Conclusión. Es necesario el uso de diferentes estrategias para un proceso diagnóstico adecuado en los tumores de la unión esofagogástrica. En esta serie, los pacientes Siewert II, aquellos que recibieron neoadyuvancia y los que obtuvieron una respuesta patológica completa, tuvieron una mejor supervivencia a tres años
Introduction: Proper diagnosis of gastroesophageal junction tumors is essential for the treatment of these patients. The classification proposed by Siewert-Stein defines its own characteristics, risk factors and surgical strategies according to the location. This study describes the characteristics of patients with adenocarcinoma of the esophagogastric junction treated at our institution. Methods. Retrospective, descriptive, longitudinal study, which includes patients diagnosed with adenocarcinoma of the esophagogastric junction who underwent surgery at the National Cancer Institute in Bogotá, Colombia, between January 2012 and May 2017. Results. Fifty-nine patients (84.7% men) were operated on, with a mean age of 62.5 years. In their order of frequency, the tumors were type II (57.6%), type III (30.7%) and type I (11.9%). 74.6% received neoadjuvant therapy and total gastrectomy was performed in 73% of the cases. The moderate diagnostic concordance with the Kappa index was 0.56, differing from the endoscopic one in 33.9%. 10.2% of the patients presented some type of intraoperative complication. Three-year survival in type II tumors was 89.6% and 100% in those with complete pathologic response. Conclusion. The use of different strategies is necessary for an adequate diagnostic process in tumors of the esophagogastric junction. In this series, Siewert II patients, those who received neoadjuvant therapy, and those who obtained a complete pathological response had a better three-year survival
Subject(s)
Humans , Esophageal Neoplasms , Esophagogastric Junction , Stomach Neoplasms , Survival , ClassificationABSTRACT
Introducción: El tratamiento principal del cáncer esofágico es la esofagectomía. Objetivo: Determinar la morbilidad y mortalidad de los pacientes operados de cáncer esofágico. Métodos: Se realizó un estudio observacional, descriptivo y transversal en 87 pacientes operados de cáncer esofágico en el Servicio de Cirugía General del Hospital Provincial Docente Saturnino Lora de Santiago de Cuba durante el período comprendido de 2014 a 2018. Resultados: Dos pacientes en estadio II (100,0 por ciento) recibieron tratamiento quirúrgico curativo y 12 en estadio III (17,9 por ciento). Recibieron tratamiento quirúrgico paliativo 55 (82,1 por ciento) enfermos en estadio III y 18 (100,0 por ciento) en estadio IV. Predominó la técnica transhiatal de Denk-Sloan-Orringer aplicada en 10 (71,4 por ciento) pacientes. La gastrostomía predominó como proceder paliativo para alimentación en 53 (76,2 por ciento) pacientes. Se reportaron 45 complicaciones; el 53,3 por ciento de tipo médica, en las que prevalecieron las respiratorias: bronconeumonía (13,3 por ciento) y distrés respiratorio (11,1 por ciento). En cambio, el 46,7 por ciento de las complicaciones fueron de tipo quirúrgicas: infección del sitio operatorio (20,0 por ciento), seguida de la fuga anastomótica (15,6 por ciento). Fallecieron 16 (18,4 por ciento) pacientes del total de la serie. Las causas de muerte predominantes fueron el distrés respiratorio (31,3 por ciento) y la disfunción múltiple de órganos (25,0 por ciento). Conclusiones: La esofagectomía abierta o mínimamente invasiva se erige como el tratamiento quirúrgico de elección para el tratamiento del cáncer esofágico con intención curativa, proceder con elevada morbilidad y mortalidad a escala mundial. Los resultados de esta investigación coinciden con los reportados en la literatura médica nacional y extranjera(AU)
Introduction: The main treatment for esophageal cancer is esophagectomy. Objective: To determine the morbidity and mortality of patients operated on for esophageal cancer. Methods: An observational, descriptive and cross-sectional study was carried out with 87 patients operated on for esophageal cancer in the general surgery service of Hospital Provincial Docente Saturnino Lora, of Santiago de Cuba, during the period from 2014 to 2018. Results: Curative surgical treatment was received by 2 patients (100.0 percent) in stage II and 12 patients (17.9 percent) in stage III. Palliative surgical treatment was received by 55 ill patients (82.1 percent) in stage III and 18 ill patients (100.0 percent) in stage IV. There was a predominance of the Denk-Sloan-Orringer transhiatal technique, applied in 10 (71.4 percent) patients. Gastrostomy predominated in 53 (76.2 percent) patients as a palliative procedure for feeding. Forty-five complications were reported, 53.3 percent of which were medical, with respiratory complications prevailing: bronchopneumonia (13.3 percent) and respiratory distress (11.1 percent). On the other hand, 46.7 percent of the complications were surgical: surgical site infection (20.0 percent), followed by anastomotic leak (15.6 percent). Out of the total series, 16 (18.4 percent) patients died. The predominant causes of death were respiratory distress (31.3 percent) and multiple organ dysfunction (25.0 percent). Conclusions: Open or minimally invasive esophagectomy stands out as the surgical treatment of choice for esophageal cancer with curative purposes, being a procedure with high morbidity and mortality worldwide. The results of this research coincide with those reported in the national and foreign medical literature(AU)
Subject(s)
Humans , Esophageal Neoplasms/etiology , Epidemiology, Descriptive , Observational Studies as TopicABSTRACT
Objective: To investigate the clinical characteristics of abnormal liver function in patients with advanced esophageal squamous carcinoma treated with programmed death-1 (PD-1) antibody SHR-1210 alone or in combination with apatinib and chemotherapy. Methods: Clinical data of 73 patients with esophageal squamous carcinoma from 2 prospective clinical studies conducted at the Cancer Hospital Chinese Academy of Medical Sciences from May 11, 2016, to November 19, 2019, were analyzed, and logistic regression analysis was used for the analysis of influencing factors. Results: Of the 73 patients, 35 had abnormal liver function. 13 of the 43 patients treated with PD-1 antibody monotherapy (PD-1 monotherapy group) had abnormal liver function, and the median time to first abnormal liver function was 55 days. Of the 30 patients treated with PD-1 antibody in combination with apatinib and chemotherapy (PD-1 combination group), 22 had abnormal liver function, and the median time to first abnormal liver function was 41 days. Of the 35 patients with abnormal liver function, 2 had clinical symptoms, including malaise and loss of appetite, and 1 had jaundice. 28 of the 35 patients with abnormal liver function returned to normal and 7 improved to grade 1, and none of the patients had serious life-threatening or fatal liver function abnormalities. Combination therapy was a risk factor for patients to develop abnormal liver function (P=0.007). Conclusions: Most of the liver function abnormalities that occur during treatment with PD-1 antibody SHR-1210 alone or in combination with apatinib and chemotherapy are mild, and liver function can return to normal or improve with symptomatic treatment. For patients who receive PD-1 antibody in combination with targeted therapy and chemotherapy and have a history of long-term previous smoking, alcohol consumption and hepatitis B virus infection, liver function should be monitored and actively managed in a timely manner.
Subject(s)
Humans , Esophageal Squamous Cell Carcinoma/drug therapy , Esophageal Neoplasms/pathology , Prospective Studies , Programmed Cell Death 1 Receptor/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Liver Diseases/etiologyABSTRACT
Objective: To examine the safety and effectiveness of inflatable video-assisted mediastinoscopic transhiatal esophagectomy (IVMTE). Methods: Totally 269 patients admitted to the Anhui Provincial Hospital of Anhui Medical University who underwent IVMTE (IVMTE group, n=47) or thoracoscopy combined with minimally invasive Mckeown esophageal cancer resection (MIME group, n=222) from September 2017 to December 2021 were analyzed retrospectively. There were 31 males and 16 females in IVMTE group, aged (68.6±7.5) years (range: 54 to 87 years). There were 159 males and 63 females in MIME group, aged (66.8±8.8) years (range: 42 to 93 years). A 1∶1 match was performed on both groups by propensity score matching, with 38 cases in each group. The intraoperative conditions and postoperative complication rates of the two groups were compared by t test, Wilcoxon rank, χ2 test, or Fisher exact probability method. Results: Patients in IVMTE group had less intraoperative bleeding ((96.0±39.2) ml vs. (123.8±49.3) ml, t=-2.627, P=0.011), shorter operation time ((239.1±47.3) minutes vs. (264.2±57.2) minutes, t=-2.086, P=0.040), and less drainage 3 days after surgery (85(89) ml vs. 675(573) ml, Z=-7.575, P<0.01) compared with that of MIME group. There were no statistically significant differences between the two groups in terms of drainage tube-belt time, postoperative hospital stay, and lymph node dissection stations and numbers (all P>0.05). The incidence of Clavien-Dindo grade 1 to 2 pulmonary infection (7.9%(3/38) vs. 31.6%(12/38), χ²=6.728, P=0.009), total complications (21.1%(8/38) vs. 47.4%(18/38), χ²=5.846, P=0.016) and total lung complications (13.2%(5/38) vs. 42.1%(16/38), χ²=7.962, P=0.005) in the IVMTE group were significantly lower. Conclusion: Inflatable video-assisted mediastinoscopic transhiatal esophagectomy combined with laparoscopic esophagectomy is safe and feasible, which can reach the same range of oncology as thoracoscopic surgery.
Subject(s)
Male , Female , Humans , Retrospective Studies , Esophagectomy/methods , Treatment Outcome , Laparoscopy , Thoracoscopy , Lymph Node Excision/methods , Esophageal Neoplasms/surgery , Postoperative ComplicationsABSTRACT
Radical resection of gastrointestinal tumors based on the membrane anatomy theory has significantly reduced the postoperative recurrence rate and improved the surgical efficacy. However, the theory of membrane anatomy has not been widely adopted in radical surgery for esophageal cancer. Our study found that the esophagus also has a membranous anatomical structure. As a foregut organ, the esophagus also has a mesenteric structure, and there is also a fifth metastasis pathway within the esophageal mesentery for esophageal cancers. The leak and metastasis of cancer caused by destruction of the mesenteric integrity may be the fundamental reason for the high postoperative recurrence rate. Using the nano carbon and indocyanine green fluorescence tracing technique, we demonstrated the lymphatic drainage of the upper esophageal segment to the left gastric artery mesenteric lymph nodes. Therefore, in the radical resection of esophageal cancer, we used the membrane anatomy theory for guidance to completely remove the esophageal cancer, esophageal mesentery, left gastric artery and its mesentery, as well as all structures within the mesentery, preventing the spread of cancer cells through the blood vessels, lymphatic system, and mesentery, and improving the efficacy and prognosis. This article elaborates on the theoretical basis of the anatomical structure of the esophageal membrane, embryonic development, imaging, autopsy, and endoscopic observation of the structure, as well as the application effect of the esophageal membrane anatomical theory in esophageal cancer radical surgery. It elucidates the anatomical structure of the esophageal membrane and the lymphatic drainage characteristics of esophageal cancer, reveals the law of lymphatic metastasis in esophageal cancer, optimizes lymphatic dissection strategies, and improves the efficacy of esophageal cancer radical surgery.
Subject(s)
Humans , Lymph Node Excision/methods , Esophageal Neoplasms/surgery , Lymph Nodes , Endoscopy , DissectionABSTRACT
Objective: To investigate the application value of computed tomography (CT) examination of lymph node short diameter in evaluating cardia-left gastric lymph node metastasis in thoracic esophageal squamous cell carcinoma (ESCC). Methods: A total of 477 patients with primary thoracic ESCC who underwent surgical treatment in the Affiliated Cancer Hospital of Zhengzhou University from January 2013 to December 2017 were collected. All of them underwent McKeown esophagectomy plus complete two-field or three-field lymph node dissection. Picture archiving and communication system were used to measure the largest cardia-left gastric lymph node short diameter in preoperative CT images. The postoperative pathological diagnosis results of cardia-left gastric lymph node were used as the gold standard. Receiver operating characteristic (ROC) curve was used to evaluate the efficacy of CT lymph node short diameter in detecting the metastasis of cardia-left gastric lymph node in thoracic ESCC, and determine the optimal cut-off value. Results: The median short diameter of the largest cardia-left gastric lymph node was 4.1 mm in 477 patients, and the largest cardia-left gastric lymph node short diameter was less than 3 mm in 155 cases (32.5%). Sixty-eight patients had cardia-left gastric lymph node metastases, of which 38 had paracardial node metastases and 41 had left gastric node metastases. The lymph node ratios of paracardial node and left gastric node were 4.0% (60/1 511) and 3.3% (62/1 887), respectively. ROC curve analysis showed that the area under the curve of CT lymph node short diameter for evaluating cardia-left gastric lymph node metastasis was 0.941 (95% CI: 0.904-0.977; P<0.05). The optimal cut-off value of CT examination of the cardia-left gastric lymph node short diameter was 6 mm, and the corresponding sensitivity, specificity and accuracy were 85.3%, 91.7%, and 90.8%, respectively. Conclusion: CT examination of lymph node short diameter can be a good evaluation of cardia-left gastric lymph node metastasis in thoracic ESCC, and the optimal cut-off value is 6 mm.
Subject(s)
Humans , Esophageal Squamous Cell Carcinoma/pathology , Cardia/surgery , Esophageal Neoplasms/pathology , Lymphatic Metastasis/pathology , Lymph Nodes/pathology , Lymph Node Excision , Tomography, X-Ray Computed/methods , Esophagectomy/methods , Retrospective StudiesABSTRACT
Objective: To retrospectively analyze the risk factors of anastomotic leakage in the neck after esophageal cancer and establish a nomogram prediction model that can accurately predict the occurrence of anastomotic leakage in the neck of the patient. Methods: The study retrospectively analyzed 702 patients who underwent radical esophageal cancer surgery between January 2010 and May 2015 at Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. A multivariate logistic regression model was used to determine the risk factors for neck anastomotic leak, and a nomogram model was constructed, internal validation methods were used to evaluate and verify the predictive effectiveness of the nomogram. Results: There were 702 patients in the whole group, 492 in the training group and 210 in the validation group. The incidence of postoperative cervical anastomotic leak was 16.1% (79/492) in 492 patients with esophageal cancer in the training group. Multifactorial analysis revealed calcification of the descending aorta (OR=2.12, 95% CI: 1.14, 3.94, P=0.018), calcification of the celiac artery (OR=2.29, 95% CI: 1.13, 4.64, P=0.022), peripheral vascular disease (OR=5.50, 95% CI: 1.64, 18.40, P=0.006), postoperative ventilator-assisted breathing (OR=5.33, 95% CI: 1.83, 15.56, P=0.002), pleural effusion or septic chest (OR=3.08, 95% CI: 1.11, 8.55, P=0.031), incisional fat liquefaction and infection (OR=3.49, 95% CI: 1.68, 7.27, P=0.001) were independent risk factors for the development of cervical anastomotic leak after esophageal cancer surgery. The results of the nomogram prediction model showed that the consistency indices of the training and external validation groups were 0.73 and 0.74, respectively (P<0.001), suggesting that the prediction model has good predictive efficacy. Conclusion: The nomogram prediction model can intuitively predict the incidence of postoperative cervical anastomotic leakage in patients with high prediction accuracy, which can help provide a clinical basis for preventing cervical anastomotic leak and individualized treatment of patients.